Intervention Review

Anticholinergics for symptomatic management of Parkinson´s disease

  1. Regina Katzenschlager1,*,
  2. Cristina Sampaio2,
  3. João Costa2,
  4. Andrew Lees3

Editorial Group: Cochrane Movement Disorders Group

Published Online: 22 JUL 2002

Assessed as up-to-date: 4 MAY 2002

DOI: 10.1002/14651858.CD003735

How to Cite

Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson´s disease. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD003735. DOI: 10.1002/14651858.CD003735.

Author Information

  1. 1

    Donauspital/SMZ-Ost, Department of Neurology, Vienna, Austria

  2. 2

    Faculdade de Medicina de Lisboa, Laboratório de Farmacologia Clínica e Terapêutica, Lisboa, Portugal

  3. 3

    University College London, Reta Lila Weston Institute of Neurological Studies, London, UK

*Regina Katzenschlager, Department of Neurology, Donauspital/SMZ-Ost, Langobardenstrasse, 122, Vienna, 1220, Austria.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 22 JUL 2002


Cited in:


This article has been cited by:

  1. 1
    Sean Austin O. Lim, Un Jung Kang, Daniel S. McGehee, Striatal cholinergic interneuron regulation and circuit effects, Frontiers in Synaptic Neuroscience, 2014, 6,


  2. 2
    John Wong, Wanwen Lan, Li Ming Ong, Louis Tong, Non-hormonal Systemic Medications and Dry Eye, The Ocular Surface, 2011, 9, 4, 212